Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chromogranin A / CHGA (Neuroendocrine Marker) (CHGA/1773R), 1mg/mL | Login | Chromogranin A / CHGA (Neuroendocrine Marker) (CHGA/1773R), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Chromogranin A / CHGA (Neuroendocrine Marker), 1mg/mL | Login | Chromogranin A / CHGA (Neuroendocrine Marker), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Prostate Specific Antigen (PSA)(3E6), 1mg/mL | Login | Prostate Specific Antigen (PSA)(3E6), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD8A (Cytotoxic- & Suppressor T-Cell Marker) (C8/1779R), 1mg/mL | Login | CD8A (Cytotoxic- & Suppressor T-Cell Marker) (C8/1779R), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD8A (Cytotoxic- & Suppressor T-Cell Marker)(N/A), 1mg/mL | Login | CD8A (Cytotoxic- & Suppressor T-Cell Marker)(N/A), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD45RB (B-Cell Marker) (PTPRC/1783R), 1mg/mL | Login | CD45RB (B-Cell Marker) (PTPRC/1783R), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| B7-H4 (Immuno-Inhibitory Protein)(B7H4/1788), 1mg/mL | Login | B7-H4 (Immuno-Inhibitory Protein)(B7H4/1788), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD79a (B-Cell Marker)(IGA/1790R), 1mg/mL | Login | CD79a (B-Cell Marker)(IGA/1790R), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| SOX2 (Transcription Factor) (SOX2/1791), 1mg/mL | Login | SOX2 (Transcription Factor) (SOX2/1791), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| SOX2 (Transcription Factor) (SOX2/1792), 1mg/mL | Login | SOX2 (Transcription Factor) (SOX2/1792), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD45RB (B-Cell Marker)(N/A), 1mg/mL | Login | CD45RB (B-Cell Marker)(N/A), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD22 / BL-CAM (BLCAM/1795), 1mg/mL | Login | CD22 / BL-CAM (BLCAM/1795), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD22 / BL-CAM (B-Cell Marker)(BLCAM/1796), 1mg/mL | Login | CD22 / BL-CAM (B-Cell Marker)(BLCAM/1796), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Ep-CAM / CD326 (Extracellular Domain) (Epithelial Marker) (EGP40/1798), 1mg/mL | Login | Ep-CAM / CD326 (Extracellular Domain) (Epithelial Marker) (EGP40/1798), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| p53 Tumor Suppressor Protein (TP53/1799R), 1mg/mL | Login | p53 Tumor Suppressor Protein (TP53/1799R), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD40 / TNFRSF5 / CD40L-Receptor(T8P2G4*A6), 1mg/mL | Login | CD40 / TNFRSF5 / CD40L-Receptor(T8P2G4*A6), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R), 1mg/mL | Login | CD34 (Hematopoietic Stem Cell & Endothelial Marker) (HPCA1/1806R), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD34 (Hematopoietic Stem Cell & Endothelial Marker)(N/A), 1mg/mL | Login | CD34 (Hematopoietic Stem Cell & Endothelial Marker)(N/A), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| MART-1 / Melan-A / MLANA (Melanoma Marker) (rMLANA/788), 1mg/mL | Login | MART-1 / Melan-A / MLANA (Melanoma Marker) (rMLANA/788), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| AKT1 (Prognostic Marker for Neuroendocrine Tumors)(AKT1/2784), 1mg/mL | Login | AKT1 (Prognostic Marker for Neuroendocrine Tumors)(AKT1/2784), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Calretinin / Calbindin 2 (Mesothelioma Marker)(CALB2/2786), 1mg/mL | Login | Calretinin / Calbindin 2 (Mesothelioma Marker)(CALB2/2786), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| CD19 (B-Lymphocyte Marker)(PDR134), 1mg/mL | Login | CD19 (B-Lymphocyte Marker)(PDR134), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Cathepsin K (Marker of Tumor Invasiveness)(CTSK/2791), 1mg/mL | Login | Cathepsin K (Marker of Tumor Invasiveness)(CTSK/2791), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Cathepsin K (Marker of Tumor Invasiveness)(CTSK/2792), 1mg/mL | Login | Cathepsin K (Marker of Tumor Invasiveness)(CTSK/2792), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||
| Cathepsin K (Marker of Tumor Invasiveness)(CTSK/2793), 1mg/mL | Login | Cathepsin K (Marker of Tumor Invasiveness)(CTSK/2793), 1mg/mL | ||||||||||||||||
|
||||||||||||||||||


